Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Danielle M. File"'
Autor:
Abdul Rafeh Naqash, Danielle M. File, Carolyn M. Ziemer, Young E. Whang, Paula Landman, Paul B. Googe, Frances A. Collichio
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two treatments modalities is unknown
Externí odkaz:
https://doaj.org/article/fa10e8cf1b604db7ad31bc7eaa8a7b14
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer
Autor:
Danielle M. File, Tomas Pascual, Allison M. Deal, Amy Wheless, Charles M. Perou, E. Claire Dees, Lisa A. Carey
Publikováno v:
Breast Cancer Res Treat
PURPOSE: This study evaluated whether patients with de novo metastatic breast cancer (MBC) have superior outcomes compared to those with recurrent MBC in a contemporary treatment era and examined factors related to outcome differentials. METHODS: Usi
Autor:
Benjamin G. Vincent, Danielle M. File, Karen P. McKinnon, Dominic T. Moore, Jeffrey A. Frelinger, Edward J. Collins, Joseph G. Ibrahim, Lisa Bixby, Shannon Reisdorf, Sonia J. Laurie, Yara A. Park, Carey K. Anders, Frances A. Collichio, Hyman B. Muss, Lisa A. Carey, Hendrik W. van Deventer, E. Claire Dees, Jonathan S. Serody
Publikováno v:
J Immunol
Previous work from our group and others has shown that patients with breast cancer can generate a T cell response against specific human epidermal growth factor 2 (HER2) epitopes. In addition, preclinical work has shown that this T cell response can
Publikováno v:
JCO Precision Oncology
Publikováno v:
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 40
Untreated, HER2+ disease is the most aggressive breast cancer phenotype; however, the development of multiple highly effective HER2-targeting drugs has transformed treatment and survival. These drugs include the anti-HER2 monoclonal antibodies trastu
Autor:
Elizabeth Claire Dees, T. Pascual, Lisa A. Carey, Allison M. Deal, Amy Wheless, Danielle M. File
Publikováno v:
Journal of Clinical Oncology. 38:1030-1030
1030 Background: Patients with de novo metastatic breast cancer (dMBC) have superior median overall survival (mOS) compared to recurrent metastatic breast cancer (rMBC). Whether patient characteristics, prior treatment, tumor stage and innate biologi
Publikováno v:
Future oncology (London, England). 14(2)
Publikováno v:
Journal of Clinical Oncology. 32:6635-6635
6635 Background: The aim of this study was to utilize a large database of patients treated in the VA to identify prognostic factors that influence survival in patients with stage IV NSCLC. Methods:...
Autor:
Danielle M. File, Carlos Arce-Lara, Jeff Whittle, Christina D. Williams, Rafael Santana-Davila, Michael J. Kelley
Publikováno v:
Journal of Clinical Oncology. 31:8090-8090
8090 Background: Second-line chemotherapy (2-L) improves overall survival (OS) in patients with metastatic NSCLC. In 2004, erlotinib and pemetrexed were approved as 2-L agents. In this study we analyze the utilization of anti-cancer agents and surviv
Publikováno v:
Journal of Clinical Oncology. 31:e17594-e17594
e17594 Background: Patients with stage III and IV lung cancer require multidisciplinary care. The Milwaukee VA is the only center within the Veterans Health Administration in the state that has a radiation oncology facility. Patients frequently trave